Aslan Pharmaceuticals Ltd at Piper Sandler Healthcare Conference Transcript
My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler. And before I begin, I am required to point out certain disclosures regarding the relationship between Piper and our next presenting company, ASLAN Pharmaceuticals.
ASLAN is developing eblasakimab, which used to be called ASLAN004 to treat atopic dermatitis, and also farudodstat, which used to be called ASLAN003 for skin autoimmune diseases.
Here from the company is my good friend, Cal Firth, Founder and CEO of ASLAN. Carl, thanks for making the trip and being with us. It's always great to see you.
Well, thanks, Ted. And great pleasure to be invited.
So Carl, perhaps you can start out by describing the target of eblasakimab and how they differ from Regeneron's blockbuster, Dupixent. You guys have done a ton of work really categorizing and characterizing these specific targets. I'd love for you to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
